Covaxin shows 50% effectiveness against symptomatic COVID-19 in real-world assessment: Lancet Study

Two doses of Covaxin are 50% effective against symptomatic COVID-19, according to the first real-world assessment of India's indigenous coronavirus vaccine published in The Lancet Infectious Diseases journal. The results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.